bm 13505 has been researched along with Myocardial Infarction in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Earl, CQ; Egan, JW; Griswold, DE; Hillegass, LM; Marshall, PJ; Smith, EF | 1 |
| Earl, CQ; Egan, JW; Smith, EF | 1 |
2 other study(ies) available for bm 13505 and Myocardial Infarction
| Article | Year |
|---|---|
Reduction of myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion by the thromboxane receptor antagonist BM 13.505.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Coronary Disease; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Neutrophils; Phenylacetates; Prostaglandin Endoperoxides, Synthetic; Rats; Rats, Inbred Strains; Receptors, Prostaglandin; Receptors, Thromboxane; Sulfonamides | 1989 |
BM 13.505, a selective thromboxane receptor antagonist, reduces myocardial infarct size following coronary artery reperfusion.
Topics: Animals; Cells, Cultured; Coronary Circulation; Coronary Vessels; Cytosol; Male; Myocardial Infarction; Myocardial Reperfusion; Phenylacetates; Rats; Rats, Inbred Strains; Receptors, Prostaglandin; Receptors, Thromboxane; Sulfonamides; Thromboxanes | 1989 |